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ABSTRACT 
CD8+ T lymphocytes are important for immunological control of infections and 
tumors. The key interaction required to initiate the process of T cell activation is the 
engagement of the T cell receptor (TCR) with a major histocompatibility complex 
(MHC) class I/peptide complex on an antigen presenting cell (APC). Depending on the 
affinity of the interaction between the TCR and MHC class I molecule, different arrays 
of signaling pathways can be activated in the T cell.   
 
Molecular alterations in the peptide bound to the MHC class I can lead to a lower 
affinity of the MHC:TCR-interaction resulting in incomplete or qualitatively different 
T-cell responses. Altered peptide ligands (APLs) exhibiting such activity are referred to 
as partial agonists and often occur naturally through genetic instability, which affects T 
cell epitopes derived from rapidly mutating viruses or tumor-associated cellular 
antigens.  
 
We studied the molecular basis of partial agonism using MHC class I/peptide tetramer 
complexes. By using tetramers assembled with a fully agonist peptide or its synthetic 
variant we could study the relationship between tetramer staining, cytokine production 
and different pathways of activation induced cell death (AICD). We found that positive 
tetramer staining correlated with at least two different activation programs in CD8+ T 
lymphocytes: full scale activation associated with Fas-dependent AICD and an 
incomplete activation followed by Fas-independent AICD.  
 
Further, we used raft-disrupting agents to assess the role of lipid rafts in determining 
the agonistic potency of different peptide ligands. We showed that overall binding of 
specific tetramers to CTLs was reduced upon raft disruption, although the half-life of 
tetramer:TCR complexes formed under these conditions was not affected. These 
findings suggest that different TCR complexes on the surface of CTLs may have 
different requirements for cholesterol and CTLs may be heterogeneous in their raft 
structure.  
 
In addition we analyzed programs of negative regulation of CD8+ T lymphocytes and 
the capacity of APLs to activate and modulate such programs. Upon specific triggering 
CD8+ T-cells become refractory to a secondary stimulus; a condition referred to 
Activation induced Non-Responsiveness (AINR). We have shown that TCR-triggering 
results in a novel degradation pathway of Lck, a kinase which plays a critical role in the 
initiation of T cell activation. Down-regulation of Lck through degradation correlated 
with AINR in CTLs. By blocking Lck degradation we could prevent the development 
of AINR. We further investigated how activation of CTLs with APLs affected Lck 
expression. The capacity of different peptide variants to induce Lck degradation 
correlated with their agonistic potency.  
 
Inefficient recognition of APLs by specific T lymphocytes is believed to contribute to 
the failure of the immune system to control certain tumor types and progressive viral 
diseases. To better understand the regulation of APL activity by immunologic help, we 
analyzed the capacity of exogenous IL-2 and IL-15 to influence different aspects of 
  
activation triggered in CTLs by either fully or partially agonistic peptide ligands. We 
showed that signals induced by the lymphokines synergize with weak TCR signaling 
induced by partially agonistic APL, converting many of these peptides from inhibitory 
to stimulatory ligands. We also demonstrated that IL-2 and IL-15 suppress induction of 
a death receptor-independent apoptotic program triggered by partially agonistic APL.  
 
In conclusion, we have analyzed the molecular basis of partial agonism in CTL 
recognition of peptide epitopes and characterized molecular changes associated with 
death and AINR in specific CTLs. We have shown that structural changes in the 
sequence of CTL peptide epitopes may decrease the affinity of MHC/TCR interactions 
and generate APLs, which not only trigger incomplete activation programs but also 
induce and modulate negative regulation programs in CTLs. This APL induced 
signaling of suppressive nature appears to be more prominent in the absence of 
immunological help, suggesting that under conditions of immune deregulation APLs 
may actively suppress CTL responses against infectious agents or tumors.    
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1 INTRODUCTION 
 
1.1 THE IMMUNE SYSTEM 
 
The immune system is our defense against the outside world. This intricate system of 
cells, structures and substances is the barrier inhibiting the establishment of both 
infections and malignant outgrowth of cancers. During the co-evolution with the 
numerous microbes in our surroundings the immune system has developed into two 
major components: the innate and the adaptive part.  
The role of the innate immune system is to be the first line of resistance against all 
kinds of foreign microbes. The protection is initiated already in the skin and mucosal 
epithelium with antimicrobial peptides and the complement system. If that barrier is 
broken, macrophages, granulocytes, dendritic cells and Natural killer cells steps in to 
continue the contest against the foreign microorganisms. These cells rely on receptors 
recognizing frequently encountered structures residing on the surface of a wide range of 
bacteria, viruses and protozoa. This part of the immune system is characterized by 
rapidity and the absence of memory. If the cells of the innate system are not able to 
eradicate the pathogen, the adaptive immune cells are later ready to assist. The cells of 
the adaptive immune system consist of immunoglobulin producing B-cells and two 
subsets of T lymphocytes. The response of the adaptive immunity is dependent on 
expansion of rare antigen-specific clones. This is likely to account for somewhat slower 
kinetics of the adaptive immune response compared to that of the innate immunity. The 
gain is the high specificity and subsequent protection from re-infection through the 
establishment of specific memory cells.  
 
The two subsets of T cell, CD4+ helper cells and CD8+ cytotoxic cells, play an 
important role in the immune surveillance against extracellular and intracellular 
infections, respectively. The CD8+ Cytotoxic T lymphocytes are responsible for the 
scanning and destruction of cells infected by viruses, intracellular bacteria or malignant 
tumor cells. 
 
 
1.2 MHC CLASS I PRESENTATION 
 
MHC molecules are plasma membrane proteins expressed by almost all nucleated cells 
in the human body. They can bind peptides derived from endogenous, bacterial or viral 
proteins. The ability of MHC molecules to present a broad spectrum of peptide antigens 
for T cell recognition is based on a compromise between high affinity and broad 
specificity. The structural solution to this, as will be discussed in detail below, is a tight 
binding of the peptide backbone to the MHC molecule supplemented by a less 
restricted interaction with the peptide side chains allowing conformational as well as 
side chain variability in the formation of a unique MHC/peptide surface for the T cell 
receptor (TCR). To further widen the variability of peptides presented each individual 
is equipped with a number of different MHC molecules.  
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1.3 ANTIGEN PROCESSING AND MHC CLASS I PRESENTATION 
 
The individual cell in the organism has to have an efficient way of showing the 
surrounding immune system whether it has been infected with an intracellular 
pathogen. The process starts with the degradation of the foreign proteins into smaller 
fragments. This is mediated by the proteasome complex, a large cylindrical multi-
subunit complex consisting of several subunits with or without proteolytic activity [1]. 
In order to get recruited to the proteasome proteins need to be ubiquitinated [2]. The 
ubiquitin molecule is a small protein that gets attached to a lysine on the target protein 
through a covalent bound whose formation is promoted by a class of enzymes called 
ubiquitin ligases (reviewed in[3, 4]). Targeted proteins are then unfolded and processed 
in the proteasome to peptides. The proteolytic activities of this enzymatic machinery 
can be divided into three major classes, chymotrypsin like activity with preferred 
cleavage after hydrophobic residues, trypsin like activity with optimal cleavage after 
basic residues and peptidylglutamyl peptide hydrolyzing activity (PGPH) cleaving after 
acidic residues. In addition, activities cleaving after branched-chain amino acids and 
small neutral residues have also been identified [5, 6].   
Proteasome degradation generates peptide fragments which have to be actively 
transported into the endoplasmic reticulum (ER) where they can associate with the 
relevant MHC I molecule. This process is mediated by the two transporter proteins 
TAP I and II located in the ER membrane [7]. Together they form a heterodimer, each 
contributing with one ATP binding domain to the complex. The transportation of 
peptides is energy dependent and requires hydrolysis of two ATP molecules resulting 
in a conformational change in the TAP complex that sends the peptide through the 
membrane into the lumen [8, 9]. The TAP complex has a preference for peptides of 8-
16 amino acids in length, which is similar to the size of peptides binding to MHC class 
I molecules. There is also a selectivity of translocation that is determined by the peptide 
sequence and, in particular, the character of its C-terminus residue [10].  
 
The MHC class I molecules are assembled in the ER with the help of chaperone 
proteins which stabilize MHC structure before binding of the peptide (reviewed in 
[11]). The heavy chain of the MHC class I is co-translationally inserted into the ER 
membrane and glycosylated. In the ER the  heavy chain binds to the chaperone protein 
calnexin enabling the binding to the light chain β2microglobulin (β2m) [12]. After the 
conversion of heavy chain into a more mature state the calnexin is released enabling the 
binding of the next chaperone protein calreticulin [13]. The heavy chain-β2m complex 
is now able to interact with the TAP/peptide complex with the help of another 
chaperone protein called tapasin [14].  Upon binding of peptide, the MHC class 
I/peptide complex (pMHC) is released from TAP and transported through the Golgi 
apparatus to the cell surface. MHC molecules which can not bind an appropriate 
peptide are unstable and will eventually be translocated into the cytoplasm and 
degraded by the proteasome.  
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1.4 MHC STRUCTURE  
 
All of the classical MHC class I and II molecules are heterodimeric cell surface 
receptors. The class I molecules are composed of a single membrane-spanning heavy 
chain divided into a α1, 2 and 3 domain paired with the soluble light-chain β2m. The 
heavy chain has a highly polymorphic region located in the α1 and α2 domains 
consisting of two α-helixes and 8 β-sheets. Together they form a cleft where a peptide 
of 8-10 amino acids in length can bind. The helixes form part of the floor and the walls 
of the groove while the β-sheets only help forming the floor. The most variable 
residues of the MHC point into this groove and up from the tops of both helices, 
conferring unique peptide-binding and TCR-binding specificity of each MHC-molecule 
(reviewed in [15]). 
 
Structure of the human MHC class I molecule.  
 
The majority of these variable residues are located in the middle of the peptide groove 
while the conserved ones are acting like anchors for the peptide in the ends of the cleft. 
These residues often have bulky aromatic side-chains, which seal off the ends of the 
peptide groove making it a closed section [15].  The majority of MHC class I molecules 
have 6 distinct pockets in their peptide binding groove. Residues that comprise each of 
the regions are approximately the same in all the defined MHC class I structures, so 
that each pocket is located in almost the same place in every MHC class I molecule. 
The first and the last pocket are conserved while the intermediates are more varying in 
size and character between different MHC class I alleles, thereby imposing different 
sequence requirements and constraints on the peptide that is bound. One consequence 
of this is that MHC class I binding peptides contain allele-specific sequence motifs 
[16]. 
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The MHC class I molecules need to bind peptides of diverse sequence with both long 
half-life and high affinity. This is accomplished by using the total sum of the binding 
energy contributed from all the residues in the binding cleft. The conserved  pockets 
flanking the peptide binding groove are responsible for the fact that the peptides are 
always oriented in a specific amino to carboxyl direction [17].  
 
 
1.4.1 MHC class I tetramers 
MHC class I tetramers are composed of recombinant MHC class I proteins produced in 
E coli, with  a biotinylation site in the heavy chain [18].  Linking four of these 
biotinylated proteins to a flourochrome-tagged streptavidine creates an excellent tool 
for detecting   the weak binding between antigen specific T cells and their cognate 
MHC class I molecule by flow cytometry or microscope. After addition of the peptide 
of interest the tetramer will bind very efficiently to specific T cells even if they are 
apparent in low frequencies [19-22]. This molecular tool has made a great impact on 
the knowledge of T cell biology.      
 
 
1.5 CYTOTOXIC T CELLS 
 
The immune system is a complex network of cells and molecules, witch functions to 
preserve the integrity of the organism by elimination of all elements being judged 
dangerous. The key players of adaptive cellular immune responses are T and B 
lymphocytes. T lymphocytes arise in the bone marrow and migrate to the thymus for 
maturation. During this process, T cells somatically rearrange gene segments, which 
combined together encode a unique antigen-binding molecule, the T-cell receptor 
(TCR). This receptor allows them to monitor almost all cells of the body and destroy 
cells posing a potential threat to the organism. 
 
The TCR contacts the MHC complex through the TCR variable domains. The affinity 
between the specific TCR and peptide/MHC is orders of magnitude weaker than that of 
a specific antibody–antigen interaction [23]. However, because the MHC molecules 
serve not only as ligands for the TCR, but also as non-antigen-specific ligands for the 
TCR co-receptors  [24]— for example, class I molecules for CD8 and class II 
molecules for CD4 — even these weak interactions are sufficient to initiate signal 
transduction in CTLs. Below I will discuss these as well as other unique features of 
MHC/TCR interactions in T cells which determines the high sensitivity and functional 
flexibility of this process. 
 
The activation of CD8+ T lymphocytes can be divided into two phases, reflecting 
different aspects of the response. In the first phase, naïve cells become activated and 
differentiate into effector cells. In the second phase the effector cells recognize antigen 
on specific target cells at the site of antigen entry or replication resulting in the 
destruction of the target cells. Depending on the differentiation stage, CTLs may 
respond with different efficiencies to signals mediated by the TCR and, therefore they 
require different levels of co-stimulatory signals for activation. Naïve cells require the 
signal via the TCR as well as via CD8 and additional co-stimulatory signals, while 
   5 
mature effector CTLs only needs stimulation through the TCR [25, 26]. CTLs can be 
divided into at least 4 different groups, naïve, effector, effector memory and central 
memory. The different states of T cell differentiation are associated with distinct 
functional and phenotypic characteristics. The naïve cells, which have yet to encounter 
their antigen are continuously recirculating between the secondary lymph nodes and the 
blood stream while the effector and memory cells modulate their expression of different 
homing molecules changing their paths of circulation. The effectors are found in 
inflamed tissues, the spleen, and the liver together with the effector memory cells. The 
circulating pattern of central memory cells more closely resembles that of naïve cells 
which circulate between the blood stream and the secondary lymph organs [27]. The 
question regarding the lineage differentiation of CTLs is still under debate [28, 29]. 
One of the models proposes that memory cells arise from effector cells which do not 
undergo AICD [30] while another model states that central memory cells arise from 
naïve cells and further differentiate into effector memory cells and at last end up as 
terminally differentiated effector CTLs [27, 31].  
 
   
1.6 TCR MEDIATED SIGNALING 
 
1.6.1 The early activation cascade 
 
The T cell receptor and co-receptors CD4 and CD8 initiate a highly sophisticated 
network of signaling cascades with the purpose of activating or inhibiting both effector 
functions and gene transcription in T cells. The most common TCR consists of a α/β 
heterodimer. The cell surface expression of the TCR occurs in the association with the 
CD3 γε, δε,  and ξξ signaling subunits ([32]and reviewed in [33]). A small subset 
expresses a variant TCR heterodimer consisting of γ/δ TCR chains. In contrast to  the 
TCR α/β complex this receptor recognizes pathogen derived glycoproteins or 
nonclassical MHC molecules [34].  
 
Upon encounter with the correct pMHC the α/β heterodimeric TCR probably dimerizes 
and promotes stabilization of the interaction with the pMHC, enabling the CD8 co 
receptor to bind non-covalently to an invariant part of the pMHC [24]. Engagement of 
CD8 has two important functions in T cell activation. It further increases the binding of 
the TCR to the pMHC and recruits the key src-kinase Lck into a position close to the 
TCR complex [35-37].  After co-ligation of the TCR with the co-receptor CD8 or CD4, 
active Lck is proximally positioned to phosphorylate tyrosine residues within the 
ITAMs located both in the CD3 molecules and in the TCRξ signaling chains [38, 39]. 
The ITAMs consist of conserved amino-acid sequence motifs D/ExYxxLx(6-8)YxxL. 
If the clustering of kinases is sufficient it leads to phosphorylation of ITAMs at both 
tyrosines on the TCRξ and a recruitment of the Syk-family kinase ZAP-70 which binds 
to the ξ-chain ITAMs via their tandem SH2 domains [40, 41]. ZAP-70 can then readily 
be phosphorylated and activated by Lck leading to further auto-phosphorylation to 
achieve its full activation [42]. ZAP-70 then phosphorylates the first wave of adaptor 
proteins, LAT, PLCγ1 and SLP-76 (reviewed in [43]).  
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 Signaling cascades stimulated by the TCR. A Schematic description of key 
components of major signaling cascades that are stimulated following 
recognition of antigen by the TCR. (Adapted from ref [44])  
 
 
1.6.2 The late activation cascade 
  
The phosphorylated LAT and SLP-76 form a complex together with PLCγ1 that recruit 
additional adaptor proteins to the proximity of ZAP-70 enabling them to be 
phosphorylated by the kinase and by this initiating the MAP-kinase pathways [45, 46].  
The phosphorylated SLP-76 recruits the adaptor protein Grb-2 that becomes activated 
by ZAP-70 [47]. This activation recruits the GTP/GDP exchange protein SoS that 
catalyzes the switch of a GDP on the Ras protein to a GTP rendering it active. The 
activation of Ras initiates the MAP kinase cascade, which involves at least three steps 
of sequential activation of kinases resulting in expression of the transcription factor fos. 
Fos is one of the two partners in the transcription factor complex AP-1 that regulates 
the transcription of many genes important for effector functions, proliferation and 
differentiation in T cells [48].  
The phosphorylated LAT/SLP-76 also recruits and activates another GTP exchange 
protein called Vav [49]. The activated form of Vav activates a protein called rac that 
initiates another MAP kinase cascade including the JNK kinase ending with activation 
of the second member of the AP-1 transcription complex c-jun [50, 51].   
 
 
1.6.3 Calcium signaling  
 
The third member in the LAT/SLP-76/PLCγ1 complex PLCγ1 also becomes active 
upon phosphorylation and catalyzes the hydrolysis of a plasma membrane phospholipid 
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called phosphatidylinositol 4,5-biphosphate (PIP2) into two products, inositol 1,4,5-
triphosphate (IP3) and diacylglycerol (DAG)[52, 53]. These two products then activate 
two distinct signaling pathways. The IP3 diffuses to the ER where it binds to specific 
receptors, opening Ca2+ channels releasing Ca2+ into the cytosol [54]. This results in a 
rapid transient rise in the cytosolic Ca2+ levels for a few minutes. This short burst of 
calcium flow from the ER is followed by a more sustained influx of calcium from the 
extracellular space. The late influx is mediated by the Ca2+ release activated Ca2+ 
channels (CRAC) that become activated following the emptying of intracellular ER 
Ca2+ stores [55]. The increased Ca2+ concentrations can in this way be kept in the cell 
for more than an hour [56]. The Ca2+ acts as a secondary signaling substance and binds 
to the regulatory protein calmodulin. The Ca2+/calmodulin complex activates the 
serine/threonine phospatase calcineurin which dephosphorylates the transcription factor 
NFAT enabling it to translocate into the nucleus. There it helps switching on the IL-2, 
IL-4 and other cytokine genes important for the T cell response.  
The other cleavage product of the PIP2, DAG activates the transcription factor NF-κB 
through the activation of an isoform of PKC, which is transported into the 
immunological synapse upon its activation (reviewed in [57, 58]).   
 
 
1.6.4 Co-stimulation 
 
The ability of naïve T cells to expand and acquire effector functions depends not only 
on the strength of the stimulus through the TCR but also on an array of co-stimulatory 
receptors present on the T cells, such as CD28 (reviewed in [59]) as well as on soluble 
factors referred to as cytokines (reviewed in [60])  
 
1.6.4.1 CD-28 Co-stimulation 
The membrane receptor CD28 is a homodimer that has been shown to enhance TCR 
induced proliferation and differentiation of naive T cells [61]. These properties have 
given the receptor the reputation of being the molecule responsible for “signal two” in 
T cells. The two signal hypothesis [25, 26] postulates that an additional signal, besides 
the TCR, is needed for the naïve T cell activation. The two CD28 ligands CD80 and 
CD86 are expressed at high levels on professional APCs [62].  It was originally thought 
that the signal delivered by the CD28 receptor contributes qualitatively to the TCR 
signaling but this view is now under debate (reviewed in [59]) giving it a more 
quantitative role.  
 
1.6.4.2 Cytokine co-stimulation   
Cellular co-stimulation may play a less important role in the biology of mature effector 
and memory CTLs because they lack expression of co-stimulatory receptors, such as 
CD28 [63]. Instead, cytokines from the γ-common chain family have an important 
function in expansion and survival of both memory and effector subsets of T-cells [64-
66].  
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1.7 MODELS OF TCR TRIGGERING 
 
1.7.1 Serial triggering 
 
The serial engagement theory of TCR triggering was formulated in the middle of the 
last decade by Valitutti and Lanzavecchia et al [67]. In their work the authors tried to 
explain how T cells can properly be activated by less than 100 specific peptide-MHC 
complexes presented by an APC [68]. According to the proposed hypothesis a single 
peptide-MHC complex can sequentially engage and trigger several TCRs as long as the 
dissociation rate of the MHC complex from the TCR is within the correct time frame. 
The simplified version of the model would imply that a TCR/CD3 complex can be 
triggered by a monovalent ligation for a minimum time (in the range between 1 and 5 
seconds). This would be the minimum time required for inducing redistribution and 
clustering of the needed kinases and phosphatases surrounding the engaged TCR, 
resulting in phosphorylation of ITAMs and further recruitment of signaling 
components. Although premature dissociation would fail to activate the TCR, 
dissociation after activation of the signaling cascade would not interfere with signal 
transduction.  
The number of TCRs that can be triggered by a single MHC depends on two factors: 
the time of ligation required for triggering and the stability of the complex. This implies 
that the optimal amount of TCRs triggered is when the two factors have equal values. 
Three assumptions have to be made in order to support this simplified model. The 
process of triggering must take place in a limited area where (i) adhesion molecules can 
facilitate the contact between the TCR and MHC/peptide complex, (ii) there is a 
saturated amount of components for the signaling machinery on the T cell side and (iii) 
new TCRs can be recruited to replace the ones being constantly downregulated. During 
the last years this model has gained support due to the increased resolution and power 
of imaging techniques [69-72].  
 
  
 
1.7.2 Kinetic proof reading 
 
An additional model that has been proposed at the same time as the serial triggering 
model is referred to as the “kinetic proofreading” model[73, 74], which attempts to 
explain the ability of the TCR to discriminate between a foreign antigen and self 
antigens with the extremely minor difference in affinity that exists. A simple physical 
model was suggested to account for this sensitivity of T cell response to ligand 
structure. The kinetic discrimination model postulates that ligands, which bind to the 
TCR for an extended duration, activate positive T cell signaling, whereas ligands that 
only bind briefly activate negative signaling. In this way the most important factor for 
the signaling becomes the dissociation rate of the TCR from the pMHC. 
This model is consistent with and elegantly explains reports on T cell receptor 
antagonism and partial agonism. A question that the model does not address is how the 
signal is sustained over a long period of time. Implementing the model of serial 
triggering in this context, the two models complement each other very nicely.  
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1.7.3 Problems with the models  
 
The models have later been modified to incorporate the idea of temporal and spatial 
summation [75], where it was proposed that signaling emanating from serially triggered 
TCRs is not only sustained but incrementally builds up. Both of the models postulated 
that the activation must take place in a secluded area. This could not experimentally be 
addressed from the beginning due to the lack of appropriate imaging techniques. A few 
years later this notion has been experimentally supported by the characterization of the 
immunological synapse [69].  
What these models still have not been able to incorporate was the observations that 
some peptide variants with a higher affinity and lower dissociation rate induce reduced 
responses [76-79]. This was elegantly explained by Kalergis et al, who proposed a 
model assuming that efficient T cell activation occurs only within a given half-life 
range for the TCR-pMHC interaction and that excessively long half-lives are 
detrimental to T cell function. This would explain previous observations which showed 
that lengthening half-life does not necessarily increase, but instead can decrease, the 
agonistic potency of pMHC variants [77, 80]. Furthermore some TCR/pMHC 
combinations seem to yield an inverse activation pattern stimulating proliferation but 
not cytotoxicity [77, 81, 82]. This is in total contradiction to what one would expect 
assuming that the stronger the interaction between the TCR and pMHC the more 
activation events are triggered in T-cells [83]. This issue still awaits the final resolution. 
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Correlation between the half-life of the TCR-pMHC interaction and TCR 
activation. Each point represents a TCR/pMHC pair. Parameters on both axes 
are expressed in relative units. (Adapted from [77]) 
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1.8 IMMUNOLOGICAL SYNAPSE 
 
Shortly after T cell activation is initiated by the engagement of the TCR with pMHC on 
the APC the T cell polarizes, remodeling the actin cytoskeleton and repositioning the 
Golgi apparatus and microtubule-organizing center (MTOC) between the nucleus and 
the T-cell/APC contact area. The contact area is termed the Supra Molecular Activation 
Cluster (SMAC) or the immunological synapse[69]. The contact area can be divided 
into the central SMAC and the peripheral SMAC compartment resembling a “bull´s 
eye” pattern [70]. The TCRs cluster in the central part while adhesion molecules such 
as ICAM-1 and LFA-1 are positioned in the outer ring-like structure. By numerous 
imaging studies most of the important signaling molecules involved in T cell activation, 
such as CD2, CD28, PKC-θ, Lck, CD4 and CD8, have now also been placed in the 
central SMAC (reviewed in [84, 85]). The precise mechanisms controlling c-SMAC 
and p-SMAC formation are still unknown although signals created by the TCR itself 
seem to be important.  
 
Initially it was proposed that the function of the c-SMAC was to help initiating T cell 
activation by driving receptor aggregation [70]. However, this view has later been 
changed and it is now known that signaling by the TCR can occur before c-SMAC 
formation is completed [86, 87]. Also, some early readouts of TCR stimulation, such as 
Ca2+ mobilization and tyrosine phosphorylation, occur before c-SMAC formation [86, 
88].  
The characterization of the immunological synapse in many ways experimentally 
grounded the assumptions made in the framework of the serial triggering theory [89]. 
The synapse creates a limited area where (i) the adhesion molecules LFA-1 residing in 
the p-SMAC can facilitate the necessary contact between the cells, (ii) all the needed 
signaling components are clustered in the c-SMAC and (iii) the polarized MTOC 
making it possible to recruit more TCR needed for triggering after down-regulation.    
 
LFA-1 TCR CD28 OVERLAY  
The mature immunological synapse. Patterns of LFA-1, TCR and CD28 interaction in a 
functional synapse between a T cell and a supported planar bilayer containing I-CAM, 
MHC and CD80  (Adapted from [84]) 
 
1.9 LIPID RAFTS 
 
Discoveries of the last decade have dramatically changed our view on the topography 
of eukaryotic cell membranes [90]. Being initially considered as a relatively uniform 
surface, today it is viewed as a highly complex arrangement of subdomains with 
multiple different structural and biochemical characteristics. The domain of interest for 
T cell activation is the cholesterol and sphingolipid enriched assembly called lipid rafts 
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[91]. Accumulating data attribute an important role for these surface assemblies in the 
activation and subsequent effector functions of T cells (reviewed in [92]).  Furthermore 
it has been pointed out that there may be differences in the composition of these 
subdomains dependent on the differentiation status of the cells, suggesting the 
possibility for yet another dimension of activation control for different subsets of T 
cells [93].  
Lipid rafts have been described as signal platforms on a vast number of different cell 
types, not only lymphocytes. The presence of the saturated sphingolipids enables the 
hydrophobic cholesterol to pack tightly together forming assemblies with less fluidity 
than the surrounding membrane. The increased rigidity together with the fact that 
certain proteins can be included or excluded from the rafts gives them an important 
regulatory role in signal transduction (reviewed in [91]). Proteins with higher raft 
affinity include GPI- anchored proteins, doubly acylated proteins, such as Src-kinases 
or cholesterol-linked and palmitoylated proteins [35, 94]. Although the mere fact that a 
protein is palmitoylated does not always necessarily mean that the protein is localized 
to rafts. Additional specific amino acid residues in the transmembrane region are often 
needed [95].   
While some molecules are constitutively associated with rafts, several components of 
the TCR signal transduction cascade are only temporarily included into rafts upon T 
cell stimulation [96].  
Conflicting data has been presented regarding the localization of important signaling 
molecules in lipid rafts in both resting and activated states of T cells, e.g the TCR [96-
98]. These contradictions are probably largely dependent on that the sucrose density 
gradient-based isolation technique, used for separation of lipid rafts, is highly sensitive 
to the temperature and detergent composition used. This may introduce a great 
variability into results obtained by different research groups.  
Methods used for analyzing lipid rafts function are mainly based on pharmacological 
disruption by treatment of cells with the membrane-impermeable cyclic oligosaccharide 
methyl-β-cyclodextrin (MβCD) or the antifungal polyene Filipin [99, 100]. They work 
by extracting or interchalating with cholesterol. The use of these methods has given rise 
to a number of concerns regarding relevance of data obtained with raft-disrupting 
reagents, because of their non-specific side effects on the treated cells.  
 
 
 
1.10 NON-RESPONSIVENESS IN CTLS 
 
The current model of T cell activation postulates that full activation requires the 
presence of at least two signals, the first provided by pMHC through the TCR and the 
second in the form of co-stimulation. The first signal ensures the specificity of the T cell 
response. The second signal involves a plethora of co-stimulatory molecules that 
regulate the proliferation, survival, and differentiation of T cells. CD28 and LFA-1 are 
the two most well-defined co-stimulatory receptors and the engagement of these 
receptors by their respective ligands, B7 and ICAM-1, is necessary for optimal IL-2 
production and clonal expansion [26, 101]. 
In contrast to naïve cells or CD4+ cells, CD8+ cytotoxic T lymphocytes cells become 
unable to proliferate or produce IL-2 subsequent to the primary TCR triggering 
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combined with the engagement of co-stimulatory molecules, such as CD-28 [102, 103].  
This functional condition of CTLs is often referred to as Activation-Induced Non-
responsiveness[104].  In anergic CD4+ T cells, expression of phospholipase C-γ1 
(PLC-γ), protein kinase C (PKC)-φ and RasGTPase-activating protein (RASGAP) is 
down-regulated [105]. Alterations in signal transduction were also reported in 
refractory CTLs [106] but the mechanisms responsible for the development and 
maintenance of AINR remain poorly defined. In mouse CTLs, AINR may be reverted 
by exogenous IL-2 [104] in contrast to human cells [107] where AINR seems to be 
reverted by IL-15 and IFN-α [108]. In contrast to CD4+ cells, the state of non-
responsiveness to secondary stimulus seems to directly correlate with the strength of 
the primary stimulation [109] and (M.Uhlin, unpublished data). 
 
1.10.1  TCR induced degradation of signaling molecules 
 
Upon TCR triggering important signaling molecules in the signaling cascade are 
internalized and degraded [108, 110-112] The TCR/CD3 complex is degraded  in the 
lysosome, ZAP-70 is degraded by calcium dependent proteases and Lck by other 
proteases. This activation-induced degradation is an effective way for T cells to 
efficiently control the activation process [86, 113]. 
The downregulation of the TCR and ZAP-70 has been shown to be transient [107, 111]  
in contrast to Lck whose expression was maintained at low levels correlating with non-
responsiveness [108] in triggered CTLs. The level of Lck expression affects its net 
activity. It is noteworthy that Lck expression is often significantly decreased in T 
lymphocytes infiltrating tumors or circulating in the blood of patients with chronic 
infections or inflammation that may play a role in the functional incapacity of T cells 
observed during cancer progression or chronic infections[114-116]. Whether this is due 
to a constant TCR triggering or a stable down modulation is uncertain.  
   
 
1.11 APOPTOSIS IN CTLS  
 
Death of T lymphocytes in response to repeated antigen-specific stimulation or 
nonspecific TCR triggering is referred to as AICD[117]. AICD is believed to account 
for eventual elimination of the vast majority of specific lymphocytes expanding in 
response to a foreign antigen and to contribute to the development of transplant or 
peripheral tolerance [118, 119]. This is a very important homeostatic function keeping 
the T cell pool at a constant level. Thus, deregulation of death receptor signaling, either 
allowing too much or too little apoptosis, can lead to autoimmune disorders and also 
impacts on tumorogenesis and other diseases 
 
 
1.11.1 Death receptor mediated AICD 
 
Death receptors belong to the tumor necrosis factor receptor (TNFR) superfamily, and 
are able to trigger apoptosis through a caspase mediated pathway. Fas (CD95) has been 
shown to trigger rapid apoptosis when ligated in activated T cells. It was reported that 
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activation-induced Fas ligand upregulation and the engagement of Fas on activated 
mature T cells resulted in AICD in vitro [120-122]. However, Fas-FasL interactions 
make a relatively minor contribution to the peripheral deletion of T cells in vivo [123, 
124] 
 
Upon stimulation of activated CTLs, CD95 ligand mRNA and protein expression are 
rapidly induced [125, 126] and increased amount of  FasL is exposed at the cell surface. 
CD95L can then bind to CD95 molecules on the same or neighboring cells and trigger 
CD95-dependent apoptosis.  
 
The pathway of Fas mediated apoptosis has been extensively studied (reviewed in [127, 
128]. Fas-mediated apoptosis involves the activation of a cascade of cystein proteases, 
called caspases. FasL is always expressed on the surface in a trimeric form and upon 
binding of Fas on the target cell trimerization of the Fas is also induced. This 
multimerization enables an adaptor protein called FADD to bind to a specific death 
domain expressed in the cytoplasmic tail of the Fas molecule. FADD can then interact 
with the pro-caspase 8 enabling the caspase to autocatalyze and selfactivate. Activated 
caspase 8 further cleaves the procaspase 3 thereby activating it and starting the caspase 
cascade. The cascade culminates by entering of the caspase dependent DNAse into the 
nucleas of the cell which fragments the DNA into 200 base pair fragments.  
 
DNA fragmentation 
Plasma membrane blebbing
ROS AIF
∆ψm
PT
Bcl-2
Bcl-2
Bcl-2
Caspase 9
Caspase 2
Caspase 3
Apaf-1
Cytochrome C
Caspase 3
dATP
Flip
Flip
FasL
Fas
TNF
TNFR
 
The Fas cell death pathway. Fas-induced cell death requires the binding of either 
membrane-bound or soluble Fas ligand to the Fas receptor on the cell surface. This 
initiates the formation of the death-inducing signaling complex (DISC), including Fas, 
FADD and caspase 8. (adapted from [129]) 
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1.11.2 Death receptor independent AICD in CTLs 
 
Although Fas-FasL interaction has been shown to play an important role in AICD of 
mature T cells, the in vivo data clearly suggests that there are additional pathways 
involved in peripheral deletion of mature CTLs [123, 124, 130].  
One important molecule that has been implicated in AICD is the pro-apoptotic bcl-2 
protein family member BH3-only protein Bim [130-132]. Recent studies using gene 
knockout mice have identified Bim as a major regulator of apoptosis in the lymphoid 
system. Bim plays a critical role in both thymic and peripheral deletion of T 
lymphocytes [130, 133, 134] and is required for B cell death, in response to 
crosslinking of surface immunoglobulins [135] Bim is regulated both at the level of 
protein expression and by posttranslational modifications such as phosphorylation 
[134]. Three major forms of Bim protein, small (BimS), large (BimL), and extra-large 
(BimEL), can be generated by alternative mRNA splicing with the BimS variant having 
the most active pro-apoptotic function [136]. Exactly how Bim performs its pro-
apoptotic function is still debated, but ectopic expression of Bim is sufficient to induce a 
drop of mitochondria membrane potential and initiate apoptosis[137]. The currently 
most accepted model suggest that Bim mediates apoptosis in mature T cells is by 
binding to anti-apoptotic proteins of the bcl-2 family, which reside in the mitochondria, 
thereby inhibiting their function [138].  
 
Bid, Bax, Bak and Bim
Upstream 
Caspases
Death Signals
Bcl-2
Bcl-2
Bcl-2
PT
AIF
ROS
∆ψm
Caspase 3 Caspase 9
Cytochrome C
DNA fragmentation 
Plasma membrane blebbing
 
Death receptor independent apoptotic pathway. Cells receive a non-receptor-mediated 
death signal to initiate the apoptotic pathway. Pro-apoptotic Bcl-2 family protein (i.e. 
Bid, Bax and Bim) are activated, resulting in a cascade of molecular events that act at 
the mitochondrion: loss of membrane potential, reactive oxygen species production, 
increased permeability and release of apoptosis-inducing factor. (adapted from [129])  
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1.12 APLS AND TCR SIGNALING 
 
TCR signaling does not act in a binary fashion described as a regulated transition from 
the on to off state in the system. Instead the TCR can be differently engaged by pMHC 
complexes to elicit a variety of functional outcomes [139, 140]. Depending on the 
capacity to activate different parameters of T cell responses, TCR ligands can be 
classified as agonists, partial agonists or antagonists. The agonistic ligands include full 
agonists, which are highly immunogenic and induce the full set of T cell effector 
functions, and weak agonists, which also induce the complete array of T cell effector 
functions but at decreased levels and only when significantly higher concentrations of 
the peptide antigen are used. Partial agonists are defined as peptides selectively 
inducing some effector functions while failing to induce others, e.g. proliferation [107, 
141]. Antagonist peptides, when presented in combination with the native, 
immunogenic peptide, can inhibit T-cell effector functions. 
 
Initially, differences in the early TCR mediated signaling between agonists, partial 
agonists and antagonists were observed in the phosphorylation pattern of the CD3 ξ 
chain [139, 142]. Full agonists induce complete tyrosine phosphorylation of the ξ 
chain, giving rise to two ξ-forms p21 and p23, tyrosine phosphorylation of the other 
cd3 subunits, δ, ε, full activation of the Lck kinase which enables a complete 
recruitment, tyrosine phosphorylation and activation of the ZAP-70 kinase. In contrast, 
engagement of the TCR with partial agonist ligands causes differential tyrosine 
phosphorylation of the CD3 ξ chain and almost no phosphorylation of the CD3 ε and 
only recruitment but no phosphorylation of ZAP-70 [139, 143]. The changes in 
phosphorylation of CD3 subunits upon triggering with partial agonists be reproduced 
by stimulating T cells with weak agonists or low concentrations of full agonist [143]. 
It is not entirely clear, how exactly the phosphorylation of the components of the TCR 
signaling machinery is initiated and what accounts for the differences in the 
phosphorylation patterns induced by different peptides. Recently, it was reported that 
either ab-crosslinking of the TCR or engagement of TCR-CD3 with a cognate pMHC 
ligand induces a conformational change that exposes a proline-rich sequence in CD3 ε 
resulting in recruitment of the adaptor protein Nck. These events occurs prior to and 
independently of tyrosine kinase activation [144, 145]. Differences in the nature or 
kinetics of this conformational change might explain the differential CD3 
phosphorylation pattern observed after T cell activation with different peptides, as well 
as the capacity of some MHC:peptide ligands to stimulate proliferation without 
cytotoxicity[81, 82].  
Additional evidence for this conformational change has been provided in the study by 
Krogsgaard et al [146]. The observation that certain pMHC with a relatively high 
dissociation rate induce stronger T cells responses than their counterparts with a lower 
dissociation-rate, could be reconciled by the demonstration that functionally more 
potent MHC:peptide ligands induce a more profound conformational change in the 
TCR upon binding increasing the exposure of the phosphorylation sites in the CD3 
subunits with a more rapid kinetics.  
 
Calcium fluxes induced by partial agonists and antagonist differ from that induced by  
full agonists [147]. The most predominant pattern of a Ca2+ increase induced by a full 
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agonist is a small sinusoidal peak followed by a sustained high response. This differs 
from the most frequent pattern of calcium response induced by partial agonists which is 
characterized by a continuous high influx without the preceding sinusoidal peak. 
Triggering with antagonists induce yet another pattern with large frequent oscillations. 
By treating T cell clones with genistein, an inhibitor of protein tyrosine kinases, 
calcium flux induced by the full agonist could be blocked but not the differential fluxes 
that could be seen in cells stimulated with partial agonists or antagonists. These calcium 
fluxes on the other hand could be blocked by a PKC specific inhibitor. This suggests 
that APLs which are unable to activate calcium flux through the usual Lck, PLCγ 
pathway are able to do it by an alternative PKC dependent pathway.  
 
Full agonist Partial agonist Antagonist  
Typical patterns of Ca2+ response in a T cell clone stimulated with various peptide 
ligands. (Adapted from [147]) 
  
 
1.13 APLS IN DISEASES  
 
The role of altered peptide ligands in different pathologic conditions is dual. In the case 
of immune responses to antigens characterized by extensive antigenic variation e.g. 
HIV, HCV or certain tumors, the role of APLs might be everything else than beneficial 
while in other situations, such as vaccination or transplantation, physiological activity 
of APLs can be exploited for the development of new treatment modalities. 
 
 
1.13.1 APLs in viral diseases 
 
Some RNA viruses encode for RNA polymerases, which lack proofreading activity, 
and because of this they produce viral genomes containing random base mutations. In 
the presence of immune selection pressure, which is exerted by CTLs against the wild-
type virus, this could facilitate preferential expansion of mutant progeny encoding 
altered epitopes that escape the recognition of effector CTLs. This phenomenon is 
especially well documented in the cases of HIV and HCV infections [148-152].  
 
Selection of virus mutants in CTL epitopes always occur in the context of viral fitness 
when the optimal variants represents the result of adaptation to prevailing conditions 
within the host environment with minimal adverse effects on virus function. With a 
certain degree of simplification, all residues in a CTL peptide epitope can be divided 
into 2 types: the anchoring residues and TCR contact residues. Non-conservative amino 
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acid substitutions in the anchoring positions decrease the affinity of peptide binding to 
the relevant MHC molecule thereby preventing its presentation. Theoretically 
mutations of this kind should be the most efficient in abrogating the recognition of 
virus infected cells by specific CTLs. Therefore, it is surprising that selection of 
mutated HIV and HCV variants often favors viral strains that carry mutations in the 
TCR contact residues of CTL epitopes [150, 151].  It has clearly been proven that there 
is a positive selection of CTL escape virus variants during primary infection and during 
the progression to AIDS or chronic HCV [148, 149, 153, 154]. Because of the rapid 
replication rate even a very small survival advantage, can in this case, rapidly increase 
the proportion of a new variant within the host altering the efficiency of the original 
CTL response. Though, it is important to remember that even if one CTL can not 
recognize an escape mutant it does not necessarily mean that all CTLs are silent. This is 
all dependent on the flexibility of the specific TCR in a given clone [155].  
 
APLs may play a role in these virus infections in multiple ways. They may act as 
decoys [156], as have been shown in cold target inhibition assays in vitro. Here target 
cells pulsed with APLs are added in excess to target cells pulsed with the original 
peptide that inhibits the killing of original targets. This decoy activity may be relevant 
in vivo particularly in lymph nodes where a high concentration of mutant virus can be 
achieved. Decoy activity seems to differ from antagonism where the agonist and 
antagonist must be presented on the same cell to observe the activity of the antagonistic 
ligand [155].   
 
It has also been reported that APLs can induce proliferation of CTLs in vitro without 
acting as targets in short term killing assays [82]. This might reflect a slower activation 
of CTLs by the APL[157]. This inversed hierarchy may have a beneficial role for the 
virus skewing the CTL repertoire into proliferation in response to virus-infected cell 
without killing it. The opposite situation where the APLs trigger cytotoxicity but not 
proliferation in the CTLs is better documented (reviewed in [158]). In this scenario it is 
also easier to understand the benefit for the mutant virus progeny against the wild type. 
After T cell activation a high proportion of the specific CTLs undergoes AICD. While 
the proliferative response is not induced the T cells will slowly extinguish themselves 
and as a result the virus that has not been eradicated can multiply to higher virus titers.  
 
In addition to eliciting no response or an altered response, APLs have been shown to 
inhibit the normal response of CTL when they are presented together with the original 
epitope on the same APC [155, 157, 159]. This phenomenon, termed antagonism, is not 
the result of competition for MHC class I binding sites with the antagonist ligands since 
the same effect is not seen when an excess of irrelevant peptides is added [155]. 
 
 
1.13.2 Antigenic sin 
 
The term “original antigenic sin” was first used to describe the antibody response to 
influenza virus.  After an initial infection, re-infection with a new virus strain increased 
the concentration of antibodies specific for the earlier infecting strain[160]. Although 
the antibodies generated during the first infection cross-reacted with the new virus they 
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still had higher affinity for the original strain. This phenomenon was adapted to CTL 
responses by Klenerman and Zinkernagel 1998 [161], when they described original sin 
in the CTL response against LCMV. They could show in vivo that mice primary 
infected with the wild type strain showed only a poor secondary response against a 
mutated variant reacting still mainly to the original strain.  
Two possible explanations for this have been proposed. The first one suggests that after 
a very strong primary CD8 response a high number of the CTLs develop into memory 
phenotype. A weakly cross reacting virus variant might because of this more easily 
reactivate these memory cells than much less abundant naïve CTL precursors. High 
frequencies of specific memory CTLs can be readily observed in both HIV and chronic 
HCV virus infections [149, 162]. It should also be taken into account that lower 
numbers of CD4+ helper cells present at more advanced stages of HIV infection make 
it more difficult to elicit a naïve CTL response.  
The second possibility is simply that memory CTLs from the primary infection remove 
APCs presenting the new viral epitope so that a new primary response is inhibited.  
The possible implications for antigenic sin can be very important for setting up 
vaccination strategies against both viruses and tumors prone to antigenic variation 
 
 
1.13.3 Vaccination and APLs 
 
The phenomenon of “antigenic sin” might have major consequences for developing a 
good candidate vaccine against highly unstable viruses such as HIV and HCV. The 
reason being that monovalent vaccinations, in the form of one peptide, could worsen 
the disease by hindering the immune system from making any natural CTL response 
against the infection, because of the already existing memory against the peptide used 
in the vaccine. This has been described in mice where the vaccination with multiple 
peptides derived from HIV showed an enhanced CD4+ response than vaccination with 
single peptides [163]. 
In the human system several polyvalent vaccines are now in the phase I trials [164, 
165]. 
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2 RESULTS AND DISCUSSION 
 
2.1 PAPER I:  
 
Tetramer binding and secretion of interferon-gamma in response to antigenic 
stimulation are compatible with a range of affinities of MHC:TCR interaction and 
distinct programs of cytotoxic T-lymphocyte activation. 
 
The low affinity of the interaction between the TCR and MHC class I does not allow 
detection of specific T cells with monomeric MHC class I molecules.  This problem 
was overcome by the invention of MHC:peptide tetramers oligomerized through 
biotinylation and subsequent binding to streptavidin molecules carrying four biotin 
binding sites [18]. Later studies, which used tetramers for the analysis of specific T cell 
populations have revealed unexpectedly high frequencies of tetramer positive cells 
expanded in response to both natural and experimental infections [166, 167]. This 
raised concerns regarding the functional relevance of tetramer binding to T cells.  
The plasticity in the interaction between MHC and TCR is large. This is reflected in the 
ability of a TCR to recognize and react with a set of peptides that can even lack any 
sequence similarity with the immunogenic peptide epitope (reviewed in [168]). 
It has been shown that tetrameric complexes assembled with APL bind to specific T 
cells [169, 170] under certain experimental conditions. With this in mind, it could be 
surmised that at least a proportion of tetramer binding T cells detected during viral 
diseases or expanded in response to other self or non-self antigens might recognize the 
relevant peptide as an APL. 
 
Binding of APL containing tetrameric complexes at 37 °C to EBV specific CTL 
clones 
 
Wei et al have previously characterized an analogue of the highly immunogenic HLA 
A11 restricted peptide epitope IVTDFSVIK (IVT) derived from the EBNA-4 protein 
expressed by Epstein Barr Virus (EBV). This analogue contains the F to Y substitution 
in position 5 (designated Y5) of the IVT peptide and has been reported to act as a 
partially agonistic APL for the IVT specific CTL clone BK289 [107, 171], triggering 
only cytotoxicity and apoptosis but no proliferation or IL-2 production. To extend our 
analysis we tested the agonistic potency of the IVT and Y5 peptides on more T cell 
clones from different donors expressing different TCRs [172]. In all three clones tested, 
the Y5 peptide could induce cytotoxicity but no proliferation, as assessed by thymidine 
incorporation. In parallel we performed tetramer staining of the three clones with IVT 
and Y5 containing tetramers at 3 different temperatures: 4, 20, and 37 °C. We could 
demonstrate binding of the APL containing tetramer to all three clones at all 
temperatures. The staining with the Y5-containing tetramer was less bright than that 
observed with the full agonist and decreased upon increased temperature but was 
always above the MFI obtained with a tetramer associated with an irrelevant peptide. 
The difference in intensity of staining of the APL containing tetramer between the 3 
different T cell clones also correlated with the agonistic potency of the peptides 
observed in functional experiments with these clones. The staining of an APL 
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containing tetramer at 37 °C is in contrast to what has been shown before by Whelan et 
al [170]. They have previously reported that HIV-specific HLA-A2 restricted cytotoxic 
T lymphocytes could efficiently bind APL containing tetramers but only at 4 °C. The 
concentrations of tetramers used in our study were lower then that used by Whelan and 
collogues, suggesting that the different observations made in the two studies could be 
explained by the higher agonistic potential of the APLs used in our model. It would be 
interesting to perform a wider screen of A2 restricted GAG specific T cell clones to 
find a T cell /APL combination that could mimic our results obtained in the EBV 
system.  
 
 
The dissociation rate of the APL containing tetramer accounts for its decreased 
binding efficiency to IVT specific CTLs 
 
In order to explain the decreased binding of the APL-containing tetramer we decided to 
test the on and off rate of the tetramer binding to the three CTL clones. The on-rates of 
the IVT and Y5 containing tetramers determined at 4 °C were comparable. The staining 
efficiency of specific T cells with either of the two tetramers decreased at a comparable 
rate as the amount of the tetramer was gradually titrated down. 
 
The off rate of the interaction was tested by tetramer dissociation experiments. T cell 
clones were stained at 4 °C with the two tetramers and subsequently cultured at 37 °C 
in a two chamber well in a large volume to inhibit rebinding, prior to FACS analysis.  
The estimated half-life of the Y5 containing tetramer was 5, 2 and less than 2 min with 
the three T cell clones tested that inversely correlated with their capacity to kill Y5 
pulsed cells. The staining intensity with the IVT tetramer increased during the first 20 
min of incubation by 25-45 % in all three clones. This was probably a result of two 
factors. It has been reported that high affinity binding tetramers can be internalized 
upon binding at 37 °C [170]. This was confirmed by stripping the tetramers from the 
surface with low pH buffer. This did not decrease tetramer staining intensity of the T 
cells suggesting that the tetramers were internalized. Another plausible reason for the 
increased MFI seen in early samples could be explained by a certain loss of tetramer 
binding from the time zero samples kept on ice for an hour.  
 
 
Ex vivo isolated and in vitro expanded IVT-specific CTLs efficiently bind an APL 
containing tetramer. 
 
To exclude the possibility that the ability of binding an APL-containing tetramer is a 
unique characteristic of the three chosen clones, tetramer staining was performed on 
polyclonal EBV-specific CTL cultures obtained from four HLA A11 positive, EBV 
seropositive individuals. All four CTL cultures contained CTLs which bound both the 
IVT and Y5 tetramer although with different intensity. The MFI of IVT tetramer 
stained cells increased at 37 °C compared to staining intensity obtained at 4 °C in 3 out 
of 4 individuals. A great proportion of IVT positive cells from three of the donors also 
stained positive for the Y5 containing tetramers. By investigating the composition of 
the CTL bulk culture from the forth donor we found that the majority of T cells 
expressed the same TCR. This TCR was shown to be identical to the TCR expressed by 
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the T cell clone, described earlier in the study, showing the lowest reactivity against the 
APL. 
Next we tested the ability of APL containing tetramers to stain IVT-specific T cells ex 
vivo from frozen or freshly isolated HLA A11 positive PBMCs. In one sample out of 
five we could find IVT specific CTLs with a frequency of 0.26 % of total PBMCs. 
Similar low frequencies of IVT specific T-cells in the peripheral blood of healthy virus 
carriers were observed by other investigators [173]. Approximately one fifth of the IVT 
specific cells also stained positive for the Y5 containing tetramer.  
Our finding that IVT specific cells of different donors can be stained by Y5 containing 
tetramer in different donors both in vitro and ex vivo demonstrates that tetramer binding 
to specific CTLs does not require a fully agonistic type of interaction between the 
specific TCR and the correct pMHC. This is in contradiction to several other reports 
that suggested that only tetramers containing fully agonistic peptides can stain 
positively at 37 °C [170, 174].    
 
 
Positive staining with an APL containing tetramer correlates with at least two 
distinct activation programs in CTLs   
 
Activation of IVT specific CTLs cells with Y5-pulsed cells triggers an alternative 
activation program [107]. To correlate this with tetramer binding the cytotoxic 
capacities of the four polyclonal cultures was tested by chromium release assay. All 
four CTL cultures were able to lyse Y5-pulsed target cells, although less efficiently 
than cells pulsed with the full agonist. This was in contrast to proliferation measured by 
thymidine incorporation, as only, IVT pulsed cells were able to effectively trigger 
proliferation of the four CTL cultures. We further wanted to investigate the capacity of 
the Y5 peptide to induce lymphokine production in IVT specific clones. CTLs triggered 
with the Y5 peptide secreted significant amounts of IFN-γ and TNF-α although the 
amounts were two to three folds lower than that produced by CTLs when stimulated 
with full agonist. In contrast the partial agonist could not induce any measurable 
amounts of IL-2 or IL-4.  
 
Our results demonstrate that the Y5-peptide acts as a partially agonistic analogue for 
IVT-specific T cells derived from different individuals and expressing structurally 
different TCRs. The program of Y5-mediated T-cell activation is characterized by 
induction of cytotoxic activity and selective triggering of IFN-γ and TNF-α secretion in 
the absence of IL-2 production and cell proliferation. We also show that this activation 
program is distinct from full activation correlated to a positive staining with APL 
containing tetramers both in vitro expanded cells and PBMCs ex vivo at 37 °C. 
 
In previous studies involving analysis of tetramer binding to CTLs, the characterization 
of the agonistic potential of peptide ligands was restricted to the monitoring of 
cytotoxic activity [170, 174]. Our results stress the importance of a more detailed 
functional analysis of peptide ligands for assessing the biologic relevance of 
tetramer/TCR interactions including thymidine incorporation or IL-2 production.  
Based on our data we propose that at least a proportion of cells staining positive for 
tetramer may recognize the relevant peptide as an APL. This phenomenon may be 
relevant for the situation developing in the course of infections by rapidly mutating 
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viruses such as HIV or HCV, where different quasi-species of the virus coexist giving 
rise to differences in peptide epitopes [148-150].  
 
 
2.2 PAPER II: 
 Pharmacological disintegration of lipid rafts decreases specific tetramer binding 
and disrupts the CD3 complex and CD8 heterodimer in human cytotoxic T 
lymphocytes. 
 
 
Cholesterol extraction from T cells inhibits the capacity of TCR and lipid raft-
associated molecules to redistribute following TCR triggering 
 
Increasing amount of data supports an important role of cholesterol-enriched membrane 
sub-domains, lipid rafts in the regulation of T cell activation [96, 175-177]. 
However the difference in composition of lipid rafts in various subsets of T cells 
remains poorly investigated. Several studies have reported differences in the molecular 
composition of lipid rafts in different stages of T cell development and differentiation 
[93, 178]. In this study we wanted to investigate the role of lipid rafts in T cell 
activation of fully differentiated effector CTLs, using EBV-specific, HLA A11 
restricted CTL clones [172, 179].  
 
Disruption of lipid rafts was accomplished by treatment of CTLs with the two lipid raft 
disrupting agents MβCD and Filipin as has been previously described [100, 176]. In 
order to visualize the disruption of lipid rafts we stained T cell clones with FITC 
labeled Cholera toxin, which is known to bind to the raft-associated ganglisoside GM1 
protein [92], together with CD3 specific antibody. In unstimulated cells both GM1 and 
CD3 appeared to be located in small patch–like clusters evenly distributed around the 
membrane, indicating a certain co-localization of the TCR/CD3 complex with lipid 
rafts exists already before activation. Whether or not the TCR localizes in lipid rafts has 
been debated, as some observations have placed it outside rafts [97], many other studies 
demonstrated that the receptors redistributes into rafts following its triggering [96] or is 
constantly associated with lipid rafts [98]. These observed differences might be 
explained by the use of T-cells representing different stages of differentiation. 
 
Upon TCR triggering by cross-linking with CD3-specific antibody we observed 
aggregation of the CD3 complexes and GM protein and the formation of a cap structure 
facing the APC.  Increasing amounts of the raft disrupting agent MβCD progressively 
blocked activation induced redistribution. These results indicated that cholesterol 
extraction or intercalation from the cell membrane inhibits the capacity of TCR 
molecules and lipid rafts to redistribute upon TCR triggering.   
 
 
Lipid raft disruption inhibits the cytotoxic capacity of CTLs 
 
To investigate the functional impact of lipid raft disruption on CTLs we tested the 
cytotoxic activity of the CTL clone BK289 against APCs pulsed with the relevant 
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peptide in a standard cytotoxic chromium release assay. The effector cells were 
pretreated with MβCD or Filipin or left untreated before addition of the peptide pulsed 
cells.  
Lipid raft disruption induces morphological changes that can be monitored by flow 
cytometry. Treated cells have different forward/side scatter profile. Such analysis 
indicated that the effect of the pharmacological treatment was reversible within 1-2 
hours. Hence we decided to add EDTA to the cytotoxicity assay in kinetics, in order to 
block possible cytotoxic activity of the CTLs after raft reconstitution. The results 
clearly showed that the cytotoxic capacity of the CTLs was initially totally abolished. 
After 1-2 hours the effect of the treated cells started to fade off correlating with the 
reversion of the lipid rafts seen by FACS analysis.   
 
It is natural to assume that raft disrupting agents act by abrogating signaling through a 
significant proportion of TCRs, either excluding TCRs from productive interactions 
with specific MHC:peptide complexes or preventing the recruitment of TCr signaling 
components. However other mechanisms can be at play It has been reported that raft 
disruption could activate Ras/Erk pathway implying that abnormal activation of 
selected signaling pathways may directly lead to inhibition of T-cell activation [99].  
  
 
Extraction of cholesterol from the cell membrane decreases the binding of MHC 
peptide tetrameric complexes to CTLs and affects the integrity of the CD3 
complex and the CD8 αβ heterodimer.  
 
In order to investigate whether the functional suppression after lipid raft disruption in 
CTLs was dependent on the level of alterations of signaling molecules in the cell 
membrane, CTLs were stained with a number of relevant antibodies and specific IVT-
tetramers after raft disruption. We showed that the binding of specific tetramer was 
reduced by 45 % upon treatment with MβCD or filipin. This was in line with previous 
observations by Drake et al [100] in a model of mouse influenza specific  response. In 
contrast to their data, however, we observed reduced binding of a conformation-
dependent CD3-specific antibody (SK7) as well as an antibody recognizing the fully 
assembled CD8 heterodimer. This could not be explained by a decrease in the surface 
expression of these structures as TCR α/β and CD8 α specific, conformation-
independent antibodies did not show decreased staining intensity. The conflicting 
observations between our and the previous studies might be explained by the use of 
different antibodies, because Drake et al, used CD3ε-specific confirmation independent 
antibodies to analyze CD3 expression in CTLs after raft disruption. Drake et al [100] 
proposed that the decreased binding of specific tetramers to T cells after disruption of 
lipid rafts could either be attributed to an unfavorable change in TCR display on the T 
cell surface, or that the decreased raft structure could influence the interaction between 
CD8 and the TCR. Because CD8 has been described to have an important stabilizing 
function in the binding of certain HLA molecules to the TCR [180], this could explain 
the decreased tetramer binding.  
Our data support a model where the observed decrease in tetramer binding is attributed 
to a disintegration of both the CD3 complex and the CD8 hetero-dimer.  
The incapacity of MβCD or filipin treated CTLs to efficiently kill peptide pulsed target 
cells is most likely explained by the disintegration of the CD3 complex. What is 
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interesting is that the disruption of the CD3 complex does not alter the expression level 
of the TCR α/β complex on the surface. This is interesting also in relation to the fact 
that surface expression of the TCR α/β complex is dependent on the structural integrity 
of the CD3 complex, in particular the ζ-chain [181].  
 
The stability of tetramer binding is not altered upon lipid rafts disruption 
 
Even though the staining intensity of specific tetramer binding to T cells decreased by 
approximately 50 % upon lipid raft disruption, a significant proportion of TCR retained 
their capacity of associating with MHC:peptide tetramers. By performing tetramer 
dissociation experiments on MβCD treated or control cells we investigated the possible 
interference of lipid rafts disruption with tetramer binding stability. 
  
CTLs were stained with either the IVT tetramer or the Y5-containing tetramer [107, 
171] for 1 hour at 4 °C and then incubated at 37 °C for different time periods ranging 
between 10 min and 1 hour before FACS analysis. We detected no significant 
difference in the kinetics of tetramer dissociation between treated and untreated cells 
both in the case of IVT tetramer and a less stable binder, the Y5-containing tetramer. 
This was in contrast to what we had predicted, reasoning that the Y5 tetramer binding, 
which has a much higher dissociation rate than the IVT tetramer [182], would be more 
sensitive to the changes in TCR/CD3 expression on the surface.   
 
The fact that the residual TCRs expressed on the surface bind the tetramers with the 
same stability as untreated cells, indicates that pharmacological disruption of lipid rafts 
results in the disaggregation of a proportion of TCR signaling complexes as well as 
their dissociation from CD8 heterodimer, while the rest of the TCR complexes retain 
their structure integrity, and capacity to associate with specific MHC molecules with 
relatively high stability.  More recent reports have demonstrated a heterogeneity of the 
molecular composition of different subtypes of lipid rafts characterized by different 
resistance to cholesterol extraction [183, 184] This could be one explanation for our 
finding. Whether subsets of TCRs with different sensitivity to cholesterol extraction 
have different functional properties is another aspect that should be investigated in the 
future.    
 
 
2.3 PAPER III:  
 
Regulation of Lck degradation and refractory state in CD8+ cytotoxic 
lymphocytes. 
 
After specific activation, CTLs enter a refractory state termed activation induced 
nonreponsiveness (AINR) characterized by their inability to respond efficiently to a 
secondary stimulus [104, 106]. Here we investigated the activation induced degradation 
(AID) of Lck and its impact on AINR in activated EBV specific cytotoxic T 
lymphocytes [107, 171].  
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TCR triggering induces a rapid and persistent Lck down regulation in activated 
human T cells 
 
We showed that AID of Lck takes place in CTLs triggered with either an agonistic 
peptide ligand or TCR specific antibody. The phenomenon was observed in CTLs of 
different specificity isolated from the three different donors and was reproduced upon 
CTL triggering with an LCL which endogenously processed and presented 
physiological levels of the relevant MHC peptide complexes. As a control we used a 
LCL transformed by an EBV strain that carries mutations in the anchoring residues of 
the relevant peptide epitopes preventing their presentation [185].  
 
To test if the activation status of the T cell affects AID of Lck we generated five T cell 
cultures by PHA activation of PBLs from five healthy donors. AID of Lck could only 
be seen in PHA blasts of all donors after two weeks of culturing in IL-2. After 1 week 
only 3 donors showed down regulation of Lck. In parallel we analyzed the percentages 
of CD4 and CD8 positive T cells in the cultures. Increased frequencies of CD8+ cells in 
the cultures positively correlated with the ability of cells to down regulate Lck upon 
triggering with CD3/28 beads (M. Uhlin unpublished observation). Stimulation of 
naïve and memory T cells isolated based on CD45 RO expression (reviewed in [29]) 
did not reveal any down regulation of Lck indicating that the phenomenon is dependent 
on the activation status of the T cells rather than on their state of differentiation. This 
conclusion was confirmed by experiments with TCR transgenic mice. Lck 
downregulation was observed after in vitro challenge with the specific peptide in 
splenocytes of animals which were immunized with the same peptide but not in 
splenocytes of naïve TCR transgenic controls. 
 
To test the kinetics of Lck down regulation by TCR triggering we collected samples of 
T cells activated for different periods of time ranging from 30 min to 120 hours and 
measured Lck expression by western blot. We observed a rapid downregulation of Lck 
expression which dropped to about 50 % of initial levels already after 30 min post 
triggering. The decline continued until about 8 hours, after which point lck expression 
stabilized at around 20-30 % of initial levels. Culturing the cells in IL-2 containing 
medium did not restore lck levels after up to 120 hours of culturing. In parallel with this 
we also measured the capacity of the T cells to respond to a secondary stimulus. In 
correlation with the AID of Lck the cells remained in a non-responsive state.  
 
 
AID of Lck is blocked by cysteine protease inhibitors 
 
The rapid down regulation of the enzyme Lck suggested that it is degraded upon 
triggering of the TCR. This has been shown before for other important signaling 
molecules in the TCR signaling cascade [111, 186, 187]. To find the responsible 
protease pathway we performed blocking experiments with a panel of protease, 
proteasome and lysosome inhibitors. Down-regulation of Lck was not affected by the 
presence of the proteasome specific inhibitors epoxomycin or lactacystin during T cell 
triggering. Nevertheless the inhibitors caused accumulation of ubiquitinated proteins in 
both activated and control CTLs, induced accumulation of p53 in unstimulated CTLs, 
and blocked AID of p53.  The observation of AID of p53 upon TCR triggering is a 
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novel finding that could be worth investigating further as a phenomenon potentially 
linking cancer development and immunity. Interestingly, the steady-state levels of Lck 
were decreased in the presence of proteasome inhibitors, whereas AID of Lck was not 
affected. In contrast, MG132, a less selective inhibitor of the proteasome, blocked 
down regulation of Lck in a dose-dependent manner. The presence of NH4Cl induced 
accumulation of the IL-15 receptor α-chain in nonactivated CTLs and further increased 
its up-regulation after CTL activation. However, NH4Cl did not affect AID of Lck, 
indicating no rule of lysosomes in the process. The cysteine protease inhibitor Z-LL-H 
structurally resembles MG132 but does not inhibit the proteasome [188]. AID of Lck 
was blocked by this inhibitor in a dose dependent manner. We also observed a rise in 
the steady state levels of ZAP-70 and ζ-chain and p53 but no but no block in the AID 
of these molecules in the presence of Z-LL-H.  
 
These results indicated that the degradation pathway of Lck is novel and distinct from 
the pathways described for the ZAP-70 and ζ-chain degradation [111, 186]. It is 
noteworthy that there appear to be at least three distinct degradation pathways for the 
proximal signaling components of the TCR signaling cascade.  
 
 
The degradation of Lck is not a prerequisite for T cell activation 
 
 
Inhibition of lck degradation by Z-LL-H does not interfere with T cell activation and 
effector functions. The capacity of BK bulk CTLs to kill target cells (A), produce IFNγ 
(B), IL-2 (C) or undergo activation-induced cell death (D) has been tested in the 
absence or presence of 20 mM Z-LL-H 
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Lck down-regulation in CD4+ T cells is enhanced upon engagement of CD28 [186] A 
possible interpretation of this is that degradation of Lck is required for efficient 
activation of T cells. To address this question we stimulated CTL in the presence of the 
Z-LL-H inhibitor. We could not see any inhibitory effect of the compound on cytotoxic 
capacity, IFN-γ or IL-2 production of the drug-treated CTLs compared to untreated 
cells. We also observed a similar level of AICD after 24 hours in both treated and 
untreated cells. In the case of IFN-γ production it was even slightly increased.  
 
 
AID of Lck plays an important role in the development of AINR in CTLs. 
 
To analyze whether the levels of Lck down regulation correlate with both the agonistic 
potency of different pMHC ligands and the extent of nonresponsiveness induced by 
different ligands in CTLs, IVT specific T cells were activated using the wild type 
peptide or two partially agonistic variants, Y5 and A8, which contain an F to Y 
substitution in position 5 or an I to A substitution in position 8. Both peptides act as 
partial agonists stimulating only some activation events while being unable to induce 
proliferation in IVT specific cells [107, 132, 171, 182]. After 1 hour of triggering, cells 
stimulated with any of the three peptides showed similar downregulation of Lck. After 
4 hours, the levels of Lck in T cells stimulated with the full agonist continued to fall 
whereas a significant reconstitution of the enzyme levels were seen in Y5 and A8 
stimulated cells. This correlated with the capacity of the cells to respond by 
proliferation to a secondary stimulation provided 48 hours later. Cells stimulated with 
the partial agonists expressed Lck at intermediate levels at this time point (M.Uhlin 
unpublished observation), which correlated with the capacity of the cells to only partly 
respond to a secondary stimulation.  
 
By treating CTLs with the Z-LL-H inhibitor we wanted to investigate whether or not 
non responsiveness against secondary stimulations can be reverted by blocking Lck 
degradation. CTL cultures or clones were stimulated by immobilized CD3-specific Abs 
in the absence or presence of Z-LL-H and transferred to new plates to prevent 
continuous CTL activation. The presence of Z-LL-H during the first CTL triggering 
inhibited Lck degradation as well as the development of AINR in these cells. 
Intermediate levels of Lck that could be seen after 48 hours in activated cells 
maintained in the presence of the inhibitor suggesting an additional mechanism of Lck 
downregulation that operates in addition to the degradation process, probably due to 
instability of Lck mRNA that has been shown previously [189].  
 
By transfecting a CTL polyclonal culture with an Lck encoding plasmid we could 
directly assess the role of Lck in AINR. 24 hours after primary stimulation we 
transfected CTLs by electroporation with a Lck plasmid or control vector and kept the 
cells overnight before secondary stimulation. Because of considerable cell death due to 
the harsh transfection procedure we could not asses AINR by proliferation, instead we 
measured intracellular IFN-γ production by FACS. Transfection with the Lck encoding 
plasmid increased the percentage of cells able to produce IFN-γ upon secondary 
stimulation. The MFI of the IFN-γ positive cells also increased. This was in contrast to 
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cells transfected with the empty vector or EGFP encoding vector where no effect could 
be seen.  
 
 
IFNα and IL-15 can reconstitute Lck expression and inhibit AINR in CTLs  
 
To find physiological signals that could affect Lck levels after primary stimulation we 
screened a large panel of cytokines. None of the tested cytokines had any affect on the 
AID of Lck measured after 4 hours. However cells stimulated in the presence of IL-15 
or IFN-α for 48 hours expressed levels of Lck comparable to that of unstimulated cells, 
which correlated with their capacity to respond to a secondary stimulation. We also 
checked the expression of a number of co-stimulatory molecules on CTLs stimulated in 
the presence of IL-15 or IFN-α but could not find any alterations.  
 
That IL-2 could neither restore Lck levels nor inhibit AINR, is consistent with our 
previously published data demonstrating that addition of IL-2 had no significant effect 
on the production of endogenous IL-2 by refractory CTLs [107]. However, refractory 
cells in mice reconstitute their responsiveness in the presence of IL-2 [104, 106]. It is 
well known that IL-15 and IFN-α can promote primary and memory CTL responses. 
IL-15 has been shown to augment CTL responses against HIV antigens in experimental 
vaccination models and in PBMCs of AIDS patients ([190-192]).  Because IL-15 and 
IFN-α are produced primarily by monocytes and subsets of dendritic cells 
(reviewed[193]), the upregulation of Lck by these lymphokines may represent one 
important mechanism responsible for the enhancing effect of innate immune activation 
on CTL responses. Decreased levels of Lck is observed in T cells isolated from patients 
with a number of pathologic conditions including tumors, chronic infections, or chronic 
systemic inflammation [115, 194, 195]. Our demonstration that low levels of Lck 
correlate with AINR in human CTLs and that reconstitution of Lck expression and 
reversion of AINR can be achieved by both pharmacologic agents and lymphokines 
opens up new possibilities for the development of new approaches to improve the 
immunologic control of tumors and infections. 
 
 
2.4 PAPER IV. 
 
 Help signals provided by lymphokines modulate the activation and apoptotic 
programs induced by partially agonistic peptides in specific cytotoxic T 
lymphocytes. 
 
It has been previously shown that peptides that bind to the MHC class I molecule with 
high affinity induce CTL activation in a help-independent manner, while suboptimal 
binders need additional signals in the form of exogenous lymphokines or CD40 
triggering [196]. To study how different forms of help modulate the CTL response to 
APL, we analyzed the capacity of IL-2 and IL-15, which represent help factors 
produced by CD4+ T cells and cells of the innate immune system, respectively, to 
modulate the cytotoxic activity, proliferation and survival of human peptide-specific 
CTLs activated by fully or partially agonistic MHC peptide ligands represented by an 
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immunogeneic fully agonistic peptide-epitope derived from the EBV encoded EBNA 4 
protein[107, 171]. 
 
 
Partial agonists acquire the capacity to induce proliferative response of IVT 
specific CTLs in the presence of exogenously provided IL-2 or IL-15  
 
By using synthetic analogs of the immunogenic HLA-A11 restricted peptide epitope 
IVT, which act as partial agonists for the majority of IVT specific clones isolated from 
different HLA matched donors [107, 171, 182], we checked their capacity to induce 
cytotoxicity and proliferation in three IVT specific CTL clones. Different levels of 
cytotoxic activity against peptide pulsed target cells were observed in all of the peptide/ 
T cell clone combinations, but only the full agonist peptide was able to induce 
proliferation in the three clones. The only exception was the combination of th e clone 
BK289 CTLs and Y5-peptide where a small proliferative response could be seen, but it 
was several folds smaller than that induced by full agonist. The addition of exogenous 
IL-2 had a very prominent effect on Y5-stimulated BK250 and BK289 clones while in 
CAR13 the major effect could be seen in cells stimulated with the W5 analogue.  The 
same effects could be seen after addition of exogenous IL-15. CAR 13 cells stimulated 
with the full agonists in the presence of the cytokines did not show any proliferation 
above background levels. This was accounted for by Fas-mediated AICD. Even though 
we could see this synergism between partially agonistic APL and lymphokines using a 
number of different clone-peptide combinations, it is clear, however, that to be able to 
stimulate CTL proliferation, a partially agonistic APL should possess a certain minimal 
agonistic activity. APLs that triggered lysis of target cells only at high peptide 
concentrations failed to stimulate proliferation even when exogenous IL-2 or IL-15 
was present. The use of such weak partial agonists may explain the results of previous 
studies in which no synergism was observed between partially agonistic APL and IL-
2 in the induction of proliferation of CD4+-specific T cells [197]. 
 
 
Triggering with partial agonists in the presence of IL-2 and Il-15 is not 
associated with alterations in the IL-2 and 15 expression or enhanced 
engagement of TCR or CD8 co-receptor 
 
In the order to unravel the mechanism behind this synergistic effect of partial agonists 
and lymphokines we analyzed the expression levels of the receptors for IL-2 and IL-15 
upon TCR triggering. There was no upregulation of CD25 on the surface upon APL 
triggering in the tested clones, and there were no alterations in expression levels upon 
treatment with either IL-2 or IL-15 compared to untreated cells. The IL-15 receptor 
expression was not altered in any way on the surface. 
 
After this we wanted to check whether signaling induced by the cytokines affected the 
efficiency of TCR engagement by analyzing the activation induced redistribution of the 
CD3 complex on the surface of CTLs. We stained CTLs with both CD3 specific 
antibodies and cholera toxin β-subunit against lipid rafts. In unstimulated cells both 
lipid rafts and CD3 complex were uniformly distributed on the surface in small patches. 
Upon triggering with full agonist, lipid rafts and TCR were redistributed and co-
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localized into the contact area between APC and T cells forming a cap structure. Cell 
stimulated with Y5 peptide did not induce distinct redistribution of rafts or the TCR in 
the contact area between APC and T cells. In a few cells a “semi-capping” could occur 
but nothing close to the cap-formations formed by full agonists. The addition of IL-2 or 
15 did not alter this pattern.  
 
The extent of TCR and CD8 down-regulation following specific TCR triggering is 
dependent on the number of peptide-MHC complexes presented by APC, the affinity of 
MHC-TCR interactions and the level of costimulation [67, 110, 186]. Stimulation with 
full agonist induced down-regulation of both CD3 and CD8 at the surface of T cells. In 
contrast, Y5-induced CD3 and CD8 down-regulation was barely detectable and was not 
enhanced or decreased upon stimulation of BK250 cells in the presence of IL-2 or 15. 
 
 
Tyrosine-phosphorylation is enhanced by IL-2 and IL-15 in T cells after TCR 
triggering by both full agonists and partial agonists 
 
We then assessed the repertoire of tyrosine-phosphorylation in CTLs before and after 
triggering with both IVT and Y5 in the presence or absence of IL-2 and 15. After 3 min 
of TCR triggering, the overall pattern of phosphorylated species did not significantly 
change in either IVT or Y5 stimulated samples, probably because of the pre-activated 
state of the expanding cells. However in both full and partial agonist triggered cells 
there was an increase in the intensity of many bands, and this effect was more 
pronounced after addition of exogenous IL-2 or IL-15. These results indicate a cross 
talk between the signaling pathways of the TCR and lymphokines receptors.  
 
Cross-talk between lymphokine receptors and the TCR at the level of STAT5 activation 
has been suggested[198], but we could not detect any enhanced STAT5 
phosphorylation when APL were combined with lymphokines in our system. The 
existence of STAT5-independent pathways leading to induction of proliferation of 
CD8+ T cells has been suggested by recent studies [199]. Therefore, the specific 
mechanisms accounting for the cooperation between APL-induced TCR triggering and 
lymphokine receptors remains to be characterized. 
 
 
AINR induced by partial agonists is reverted by IL-2 or IL-15 
 
It has previously been shown that TCR triggering with a full agonist results in AINR in 
our model system [107, 108]. We have also shown that triggering with altered peptide 
ligands results in partial inhibition of responsiveness, the extent of which correlated 
with the agonistic activity of these ligands [108]. What we could show in this study was 
that the APL-induced AINR appeared to be qualitatively different from AINR induced 
by the full agonist, because it could be completely reverted by culturing of the APL 
activated cells in IL-2 while full agonist activated cells remained non-responsive.  
 
In agreement with our previous data AINR induced by the full agonist was partially 
reverted by IL-15 [108]. These data suggest that sustained high-affinity T cell response 
to chronic antigens may be more dependent on continued activation of cells from the 
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innate immune system producing IL-15 rather than on CD4 produced IL-2. 
Conceivably, different immunogenic peptides may elicit CTL responses of different 
affinity due to different levels of peptide presentation on APC or differences in the 
available TCR repertoires. This may be at least partly responsible for the discrepancy 
existing in the literature regarding the requirement for different help signals in the 
induction or maintenance of specific CTL responses. 
 
 
Exogenous IL-2 or IL-15 suppress upregulation of the pro-apoptotic protein Bim 
and inhibit apoptosis in CTLs 
 
Partially agonistic peptides can induce death receptor independent apoptosis, which is 
associated with the up regulation of the pro-apoptotic member of the Bcl-2 protein 
family Bim [132]. By addition of IL-2 or IL-15 about a third of the cells undergoing 
AICD upon triggering with the partial agonist W5 could be rescued. This correlated 
with the ability of the two cytokines to suppress the up regulation of Bim. In contrast 
the recovery of cells triggered with the full agonist was not affected by exogenous IL-2 
or IL-15.  
 
Our data would suggest the following model: In the presence of functional CD4+ help 
or ongoing activation of monocytes and dendritic cells, partially agonistic peptides will 
act as null peptides or weak stimulators as the Y5 or W5 peptide in this study. In the 
absence of help, the latter group of partial agonists is converted to inhibitory peptides 
that do not stimulate proliferation of specific CTL, suppress their responsiveness to 
repeated stimulation and actively induce apoptosis, which is predominantly death 
receptor independent. This change of biological activity of the partial agonist may 
contribute to the failure of CTL responses against viruses or tumors characterized by 
frequent mutations in CTL epitopes and dysfunctional CD4+-specific T cell responses. 
Incomplete or defective activation of monocytes and dendritic cells or loss of their 
numbers, frequently observed during tumor progression or chronic viral infections, may 
also contribute to the process, decreasing the levels of available IL-15. In support of 
this model, several recent studies demonstrated a temporal link between lack or 
inhibition of CD4 help and increased frequency of new viral quasi-species appearing in 
the course of HIV and hepatitis C virus infections [152, 200]. As mutations in CTL 
epitopes can be observed already at very early stages of HIV infection [201], 
comparison of the biological effects of mutations selected in the acute or late stage of 
the disease may be particularly interesting in light of our model. Escape from 
recognition by specific CTL with restricted TCR usage, antagonistic activity against 
immunogenic peptide ligands (reviewed in [202, 203]) and the phenomenon of 
antigenic sin [161] were suggested to explain the negative effect of epitope variants on 
specific CTL responses. It is possible that each given peptide variant can escape CTL 
recognition or affect CTL function through a combination of several mechanisms. In 
fact, some of the APL used in this study exhibited antagonistic activity against IVT-
specific CTL. However, this effect was observed only for selected clones expressing 
particular types of IVT-specific TCR upon co-presentation of the IVT peptide and the 
relevant APL by the same APC (V.L., unpublished data). The results of this study 
suggest that active suppression of specific CTL responses in the absence of help signals 
is a common activity exhibited by a large proportion of APL. Detailed analysis of this 
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effect may result in new strategies for improving immune control over viruses and 
tumors. 
  
Exogenous IL-2 or IL-15 present 
Exogenous IL-2 or IL-15 absent
Proliferation Fas mediated 
AICD
+
Bim mediated
AICD
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APL induced
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CTLs
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/+
  
 
The impact of exogenous IL-2 and IL-15 on functional parameters of CTL response 
induced by partial agonistic APLs.    
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3 CONCLUSIONS 
 
In this thesis we have analyzed the molecular basis of partial agonism in CTL 
recognition of altered peptide ligands and characterized molecular changes associated 
with death and AINR in specific CTLs. From the studies that has been presented the 
following can be concluded:  
 
We showed that specific staining of CTLs with tetrameric MHC:peptide complexes is 
compatible with at least two activation programs which can be induced in these cells 
following recognition of APCs presenting the corresponding peptides on their surface. 
Of of these programs includes full-scale CTL activation and death of a proportion of 
activated T-cells in a Fas dependent manner, while the alternative program is 
characterized by induction of IFN-γ and TNF-α, absence of proliferative response and 
Fas-independent cell death.  
 
Pharmacological disruption of lipid rafts in human CTL clones disturbs the integrity of 
the CD3 complex and CD8 heterodimer, without affecting the reactivity with T-cell 
receptor (TCR)-specific antibodies.  
 
The effect of raft disruption on CD3 and CD8 expression correlates with failure to bind 
specific tetrameric complexes of different agonistic potency by a proportion of surface 
TCR molecules.  
 
Interaction of specific tetramer with the rest of surface TCR pools appears to be 
unaffected, demonstrating that TCR-signaling complexes may differ in their 
requirement for cholesterol to stably maintain their composition and to rearrange for 
efficient tetramer binding 
 
T cell receptor triggering results in rapid degradation of the protein kinase lck through a 
mechanism that is distinct from the pathways involved in degradation of ZAP-70 
kinase or ξ-chain of the CD3 complex.  
 
Pharmacologic blockade of lck degradation, as well as transfection of refractory cells 
with an lck expression vector, increases responsiveness of CTLs to repeated antigenic 
challenge. 
 
Exposure of exogenously added IL-15 or IFN-α restores both lck expression and 
responsiveness of preactivated CTLs.  
 
AINR induced by APLs can be reverted by both IL-2 and IL-15.  
 
Signals induced by the lymphokines IL-2 and IL-15 synergize with weak TCR 
signaling induced by partially agonistic APL, converting some of these peptides from 
inhibitory to stimulatory ligands.  
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IL-2 and IL-15 suppress both up-regulation of the Bim, and induction of a death 
receptor-independent apoptotic program triggered by partially agonistic APLs 
 
The results of these studies improve our understanding of CTL biology and may be 
important in the development of new approaches to vaccination and immunotherapy. 
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